TransgeneLTS:0OCQ +0.55%49 Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus rates LTS:0OCQ with a GF Score™ of 49/100 and a GF Value™ of €0.52 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 133 Biotechnology companies, Transgene ranks worse than 751878.95% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Transgene's Dividend Payout Ratio for the
months ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Transgene's Dividend Payout Ratio or its related term are showing as below:
LTS:0OCQ's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.44 * Ranked among companies with meaningful Dividend Payout Ratio only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Transgene (LTS:0OCQ) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Transgene Dividend Payout Ratio Related Terms
Transgene Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Transgene's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0OCQ vs VRTX, REGN, ALNY: Dividend Payout Ratio Comparison
For the Biotechnology subindustry, Transgene's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgene Dividend Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgene's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Transgene's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Transgene's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgene (LTS:0OCQ) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Transgene and its competitors. According to the industry distribution chart, Transgene ranks #999999 out of 133 companies in the Biotechnology industry.
Is Transgene's Dividend Payout Ratio too high?
Transgene's current Dividend Payout Ratio is 0.00. Based on the distribution chart, Transgene ranks #999999 out of 133 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Transgene has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transgene's Dividend Payout Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgene ranks #999999 out of 133 companies for Dividend Payout Ratio. This places Transgene in the lower half of its industry. The industry median Dividend Payout Ratio is 0.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.44, based on 133 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Transgene and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transgene's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene stock overvalued right now?
Based on GuruFocus' analysis, Transgene (LTS:0OCQ) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.52, compared to a current price of €0.73 — trading 41.2% above its estimated fair value. The current Dividend Payout Ratio is 0.00. Transgene's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Transgene (LTS:0OCQ), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgene (LTS:0OCQ) Overvalued in 2026?
Based on GuruFocus' analysis, Transgene stock appears to be overvalued.
The current stock price of €0.73 is trading 41.2% above its estimated GF Value™ of €0.52.
GuruFocus considers Transgene to be Significantly Overvalued.
Key valuation signals for LTS:0OCQ:
Dividend Payout Ratio: 0.00
GF Value™: €0.52 vs. price of €0.73 (41.2% above fair value)
No single metric tells the full story. See the LTS:0OCQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
49GF Score
Get the complete analysis for LTS:0OCQ
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0OCQ has been successfully added to your 
